[Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].

Abstract excerpt

Cetuximab is a monoclonal antibody that inhibits human epidermal growth factor receptor, and was approved for metastatic advanced colorectal cancer (mCRC) in 2008 in Japan. Evidences confirming the efficacy of cetuximab have been accumulated in western countries. As the first- and second-line therapy, cetuximab plus chemotherapy showed longer survival compared with chemotherapy alone. As a third-line...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Monoclonal
• Share to Antibodies, Monoclonal, Humanized